X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): T20K
Therapeutic Area: Immunology Product Name: T20K
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2021
Details:
While Cyxone continues to develop the oral administration form for T20K, the company has also decided to initiate a feasibility study on a subcutaneous administration form in Q2 2021. Finally, biomarker development to support both administration forms will be completed.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): T20K
Therapeutic Area: Immunology Product Name: T20K
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Professor Rikard Holmdahl
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 08, 2020
Details:
The agreement will support Cyxone to develop their drug candidates T20K and Rabeximod and bring them closer to the market.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
